The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene Expression
Open accessAbstract
Purpose: Breast cancer arising in young women is correlated with inferior survival and higher incidence of negative clinicopathologic features. The biology driving this aggressive disease has yet to be defined. Patients and Methods: Clinically annotated, microarray data from 784 early-stage breast cancers were identified, and prospectively defined, age-specific cohorts (young: ≤ 45 years, n = 200; older: ≥ 65 years, n = 211) were compared by prognosis, clinicopathologic variables, mRNA expression values, single-gene analysis, and gene set enrichment analysis (GSEA). Univariate and multivariate analyses were performed. Results: Using clinicopathologic variables, young women illustrated lower estrogen receptor (ER) positivity (immunohistochemistry [IHC], P = .027), larger tumors (P = .012), higher human epidermal growth factor receptor 2 (HER-2) overexpression (IHC, P = .075), lymph node positivity (P = .008), higher grade tumors (P < .0001), and trends toward inferior disease-free survival (DFS; hazard ratio = 1.32; P = .094). Using genomic expression analysis, tumors arising in young women had significantly lower ERα mRNA (P < .0001), ERβ (P = .02), and progesterone receptor (PR) expression (P < .0001), but higher HER-2 (P < .0001) and epidermal growth factor receptor (EGFR) expression (P < .0001). Exploratory analysis (GSEA) revealed 367 biologically relevant gene sets significantly distinguishing breast tumors arising in young women. Combining clinicopathologic and genomic variables among tumors arising in young women demonstrated that younger age and lower ERβ and higher EGFR mRNA expression were significant predictors of inferior DFS. Conclusion: This large-scale genomic analysis illustrates that breast cancer arising in young women is a unique biologic entity driven by unifying oncogenic signaling pathways, is characterized by less hormone sensitivity and higher HER-2/EGFR expression, and warrants further study to offer this poor-prognosis group of women better preventative and therapeutic options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Genomic signatures to guide the use of chemotherapeutics
Potti, A., Dressman, H. K., Bild, A., Riedel, R. F., Chan, G., Sayer, R., Cragun, J., Cottrill, H., Kelley, M. J., Petersen, R., et al. (2006) · Nature Medicine · doi:10.1038/nm1491 · Cited by 593
Self-citationRetractedSubramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Harrell, F. E. (2001) · Springer Series in Statistics · doi:10.1007/978-1-4757-3462-1 · Cited by 9,195
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091 · cited 1×
“Previous studies report lymph node positivity among 40% to 55% of patients with triple-negative breast cancer versus 30% within our complete data set.(33,35) Because triple-negative breast cancer is a more aggressive phenotype, our data set likely represent a better prognosis sample of patients with an overall lower l…”
BackgroundRace, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., Karaca, G., Troester, M. A., Tse, C. K., Edmiston, S., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2492 · Cited by 3,819
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
Wang, Y., Klijn, J. G., Zhang, Y., Sieuwerts, A. M., Look, M. P., Yang, F., Talantov, D., Timmermans, M., Meijer-van Gelder, M. E., Yu, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17947-1 · Cited by 2,846
Self-citationOncogenic pathway signatures in human cancers as a guide to targeted therapies
Bild, A. H., Yao, G., Chang, J. T., Wang, Q., Potti, A., Chasse, D., Joshi, M.-B., Harpole, D., Lancaster, J. M., Berchuck, A., et al. (2006) · Nature · doi:10.1038/nature04296 · Cited by 2,032
Self-citationCoussens, L., Yang-Feng, T. L., Liao, Y.-C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., et al. (1985) · Science · doi:10.1126/science.2999974 · Cited by 1,814
Concordance among Gene-Expression–Based Predictors for Breast Cancer
Fan, C., Oh, D. S., Wessels, L., Weigelt, B., Nuyten, D. S. A., Nobel, A. B., van't Veer, L. J., & Perou, C. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052933 · Cited by 1,341
Chang, H. Y., Nuyten, D. S. A., Sneddon, J. B., Hastie, T., Tibshirani, R., Sørlie, T., Dai, H., He, Y. D., van't Veer, L. J., Bartelink, H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409462102 · Cited by 981
Chang, H. Y., Sneddon, J. B., Alizadeh, A. A., Sood, R., West, R. B., Montgomery, K., Chi, J.-T., Rijn, M. V. D., Botstein, D., & Brown, P. O. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020007 · Cited by 951
Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
van der Groep, P., Bouter, A., van der Zanden, R., Menko, F. H., Buerger, H., Verheijen, R. H. M., van der Wall, E., & van Diest, P. J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh114 · Cited by 798
Akiyama, T., Sudo, C., Ogawara, H., Toyoshima, K., & Yamamoto, T. (1986) · Science · doi:10.1126/science.3012781 · Cited by 796
Genetic Reclassification of Histologic Grade Delineates New Clinical Subtypes of Breast Cancer
Ivshina, A. V., George, J., Senko, O., Mow, B., Putti, T. C., Smeds, J., Lindahl, T., Pawitan, Y., Hall, P., Nordgren, H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4414 · Cited by 752
Nixon, A. J., Neuberg, D., Hayes, D. F., Gelman, R., Connolly, J. L., Schnitt, S., Abner, A., Recht, A., Vicini, F., & Harris, J. R. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.5.888 · Cited by 579
The Relation between Survival and Age at Diagnosis in Breast Cancer
Adami, H.-O., Malker, B., Holmberg, L., Persson, I., & Stone, B. (1986) · New England Journal of Medicine · doi:10.1056/nejm198608283150906 · Cited by 549
Age as prognostic factor in premenopausal breast carcinoma
de la Rochefordière, A., Campana, F., Fenton, J., Vilcoq, J. R., Fourquet, A., Asselain, B., Scholl, S. M., Pouillart, P., Durand, J.-C., & Magdelenat, H. (1993) · The Lancet · doi:10.1016/0140-6736(93)92407-k · Cited by 480
Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?
Aebi, S., Gelber, S., Castiglione-Gertsch, M., Gelber, R., Collins, J., Thürlimann, B., Rudenstam, C., Lindtner, J., Crivellari, D., Cortes-Funes, H., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02292-3 · Cited by 287
BRCA1 Mutations in a Population-Based Sample of Young Women with Breast Cancer
Langston, A. A., Malone, K. E., Thompson, J. D., Daling, J. R., & Ostrander, E. A. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601183340301 · Cited by 286
Ahn, S. H., Son, B. H., Kim, S. W., Kim, S. I., Jeong, J., Ko, S.-S., & Han, W. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.3754 · Cited by 279
Effects of young age at presentation on survival in breast cancer
El Saghir, N. S., Seoud, M., Khalil, M. K., Charafeddine, M., Salem, Z. K., Geara, F. B., & Shamseddine, A. I. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-194 · Cited by 268
Breast cancer outcome and predictors of outcome: are there age differentials?
Albain, K. S., Allred, D. C., & Clark, G. M. (1994) · PubMed · Cited by 264
Malone, K. E., Daling, J. R., Thompson, J. D., O'Brien, C. A., Francisco, L. V., & Ostrander, E. A. (1998) · JAMA · doi:10.1001/jama.279.12.922 · Cited by 249
Vleugel, M. M., Greijer, A. E., Shvarts, A., van der Groep, P., van Berkel, M., Aarbodem, Y., van Tinteren, H., Harris, A. L., van Diest, P. J., & van der Wall, E. (2005) · Journal of Clinical Pathology · doi:10.1136/jcp.2004.019885 · Cited by 227
Gong, Y., Yan, K., Lin, F., Anderson, K., Sotiriou, C., Andre, F., Holmes, F. A., Valero, V., Booser, D., Pippen, J. E., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70042-6 · Cited by 195
The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications
Honrado, E., Benítez, J., & Palacios, J. (2005) · Modern Pathology · doi:10.1038/modpathol.3800453 · Cited by 190
Harrell, F. E. (2001) · Springer series in statistics · doi:10.1007/978-1-4757-3462-1_13 · Cited by 182
Management of Menopausal Symptoms
Grady, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmcp054015 · Cited by 180
Therapeutic Implications of the Cancer Stem Cell Hypothesis
Diehn, M., Cho, R. W., & Clarke, M. F. (2009) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2008.11.002 · Cited by 145
12. Management of Menopausal Symptoms
Martin, K. A., & Manson, J. E. (2010) · The Endocrine Society eBooks · doi:10.1210/caem1.9781936704606.ch12 · Cited by 142
Hartley, M. C., McKinley, B., Rogers, E. A., Kalbaugh, C. A., Messich, H. S., Blackhurst, D. W., Lokey, J. S., & Trocha, S. D. (2006) · The American Surgeon · doi:10.1177/000313480607201208 · Cited by 58
Research works printed but not linked: 7
- 10.1016/S0959-8049(97)89017-X · doi:10.1016/s0959-8049(97)89017-x
- 10.1038/bjc.1997.223 · doi:10.1038/bjc.1997.223
- 10.1016/S0140-6736(05)70933-8 · doi:10.1016/s0140-6736(05)70933-8 · Paper page
- Kim C, Tang G, Baehner F, et al: A comparison of estrogen receptor (ER) measurement by three methods in node negative, estrogen receptor (ER) positive breast cancer: Ligand binding (LB), immunohistochemistry (IHC), and quantitative RT-PC. 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 14-17 , 2006 (abstr 3116)
- 10.1023/A:1006498721508 · doi:10.1023/a:1006498721508
- 10.1093/jnci/djh115 · doi:10.1093/jnci/djh115
- 10.1097/00008571-200204000-00012 · doi:10.1097/00008571-200204000-00012
Cited by
Ma, J., & Jemal, A. (2013) · Breast Cancer Metastasis and Drug Resistance · doi:10.1007/978-1-4614-5647-6_1 · Cited by 1,907
Feng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., Ji, X., Liu, W., Huang, B., Luo, W., et al. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.05.001 · Cited by 1,486
Fan, L., Strasser-Weippl, K., Li, J.-J., St Louis, J., Finkelstein, D. M., Yu, K.-D., Chen, W.-Q., Shao, Z.-M., & Goss, P. E. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70567-9 · Cited by 1,397
Breast Cancer Before Age 40 Years
Anders, C. K., Johnson, R., Litton, J., Phillips, M., & Bleyer, A. (2009) · Seminars in Oncology · doi:10.1053/j.seminoncol.2009.03.001 · Cited by 791
Self-citationEpidemiology of breast cancer in Indian women: Breast cancer epidemiology
Malvia, S., Bagadi, S. A., Dubey, U. S., & Saxena, S. (2017) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12661 · Cited by 784
Metadata
- Authors
- Anders, C. K., Hsu, D. S., Broadwater, G., Acharya, C. R., Foekens, J. A., Zhang, Y., Wang, Y., Marcom, P. K., Marks, J. R., Febbo, P. G., Nevins, J. R., Potti, A., & Blackwell, K. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-07-10
- Volume
- 26
- Issue
- 20
- Pages
- 3324-3330
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2161849165
- Cited by
- 911
- References
- 37
- FWCI
- 11.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.